EVTCY / Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

Evotec's Seattle-based subsidiary has won a $74 million contract with the U.S. Department of Defence to develop monoclonal antibody-based drugs target more_horizontal

Bayer AG BAYRY has discontinued the development of eliapixant and will hand back full rights to the drug to Evotec SE EVO. Get the Inside Access more_horizontal

Bayer AG BAYRY has discontinued the development of eliapixant and will hand back full rights to the drug to Evotec SE EVO. Get the Inside Access more_horizontal

Bayer AG BAYRY has discontinued the development of eliapixant and will hand back full rights to the drug to Evotec SE EVO. Get the Inside Access more_horizontal

-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Thera more_horizontal

-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Thera more_horizontal

-- Company contracts leading global drug development company to advance initial drug candidate -- Miami Beach, FL / October 11, 2021 -- Pasithea Thera more_horizontal

Bristol Myers Squibb & Co (NYSE: BMY) has expanded its neuroscience collaboration with Evotec SE (OTC: EVTCY) to include a new cell type. Related more_horizontal